Tamara D. Cabalu
Merck & Co., Inc., Rahway, NJ, USA (United States)(US)United States Military Academy(US)Health First(US)
Publications by Year
Research Areas
Sleep and Wakefulness Research, Sleep and related disorders, Pharmacogenetics and Drug Metabolism, Circadian rhythm and melatonin, Photochromic and Fluorescence Chemistry
Most-Cited Works
- → Discovery of the Dual Orexin Receptor Antagonist [(7R)-4-(5-Chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the Treatment of Insomnia(2010)370 cited
- → Drug–Drug Interaction Studies: Regulatory Guidance and An Industry Perspective(2013)240 cited
- → Discovery of [(2R,5R)‐5‐{[(5‐Fluoropyridin‐2‐yl)oxy]methyl}‐2‐methylpiperidin‐1‐yl][5‐methyl‐2‐(pyrimidin‐2‐yl)phenyl]methanone (MK‐6096): A Dual Orexin Receptor Antagonist with Potent Sleep‐Promoting Properties(2012)121 cited
- → Discovery of 5′′‐Chloro‐N‐[(5,6‐dimethoxypyridin‐2‐yl)methyl]‐2,2′:5′,3′′‐terpyridine‐3′‐carboxamide (MK‐1064): A Selective Orexin 2 Receptor Antagonist (2‐SORA) for the Treatment of Insomnia(2013)67 cited
- → Recommendations for the Design of Clinical Drug–Drug Interaction Studies With Itraconazole Using a Mechanistic Physiologically‐Based Pharmacokinetic Model(2019)46 cited
- → In vitro and characterisation of the metabolism and disposition of suvorexant in humans